A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Give P values as exact values whenever suitable.
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated Our web collection on statistics for biologists contains articles on many of the points above.
Software and code
Policy information about availability of computer code
Data collection

Data analysis
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Data
Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: Studies were done with CCN1 proteins from the lab and replicated with CCN1 proteins obtained from two commercial sources with distinct cellular origins and different purification methods.
N/A N/A anti-CCN1 Ab (from house; 1:2000 dilution for solid phase binding and 1:100 for flow cytometry); polyclonal anti-S. aureus (ab20920; 1:2000 dilution for solid phase binding and 1:100 dilution for IHC), anti-P. aeruginosa (ab68538; 1:500 dilution for solid phase binding), anti-S. pneumonea (ab20429; 1:2000 dilution for solid phase binding), and monoclonal anti-S. Typhimurium antibodies (ab8274; 1:1000 dilution for solid phase binding) (Abcam); anti-hTLR2 (MAB2616, 1:100 dilution for solid phase binding and 1:1000 dilution for dot blot), anti-hTLR4 (AF1478; 1:100 dilution for solid phase binding and 1:1000 dilution for dot blot), or anti-hCD14 antibodies (MAB3832; 1:100 for solid phase binding) (R&D systems); monoclonal anti-iC3b antibody (EMD Millipore, MABF972; 1:200 dilution); allophycocyanin (APC)-conjugated goat anti-rabbit IgGs (Life Technologies Co.; A10931, 1:250 dilution;) or APC-conjugated rat anti-mouse IgGs (Life Technologies Co.; 17-4015-82, 1:500 dilution); Alexafluor488conjugated anti-rabbit IgG (Invitrogen, 1:500 dilution) anti-CCN1 antibody was validated in Western blot analysis, immunohistochemistry and flow cytometry. Each antibody validation can be found in each company's web site.
All cell lines were obtained from American Type Culture Collection.
For L929 cells, morphology and ability of conditioned media for macrophage differentiation were used for authentication. For THP.1 cells, morphology and PMA-induced differentiation was used.
All cell lines were tested negative for Mycoplasma contamination using commercial kit. none
